SyntekaBio

SyntekaBio Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 168.92. In the previous year, Cash Conversion Cycle (CCC) was 182.43 — a change of -7.41% (lower).

Cash Conversion Cycle

168.92

YoY

-7.41%

Last updated:

Cash Conversion Cycle (CCC) of SyntekaBio is 2022 168.92 . Cash Conversion Cycle (CCC) of SyntekaBio was 2021 182.43 . It decreases by -7.41% lower compared to the previous year.

The SyntekaBio Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2017
8.39 KRW
Jan 1, 2018
180.86 KRW
Jan 1, 2019
129.74 KRW
Jan 1, 2020
162.84 KRW
Jan 1, 2021
182.43 KRW
Jan 1, 2022
168.92 KRW
The SyntekaBio Cash Conversion Cycle history
YEARCash Conversion CycleYoY
168.92-7.41%
182.43+12.03%
162.84+25.51%
129.74-28.26%
180.86+2,054.65%
8.39—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Cash Conversion Cycle (CCC) of SyntekaBio is 168.92 in 2022.

Cash Conversion Cycle (CCC) of SyntekaBio changed from 182.43 to 168.92, representing a -7.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s SyntekaBio with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SyntekaBio

All Key Metrics — SyntekaBio